NASDAQ, EXEL - Exelixis Inc
We are committed to developing innovative therapies for cancer and other serious
diseases. Through our integrated drug discovery and development activities, we
are building a portfolio of novel compounds that we believe have the potential
to be high-quality, differentiated pharmaceutical products. Our most advanced
pharmaceutical programs focus on discovery and development of small molecule
drugs for cancer.
Utilizing our library of more than 4.5 million compounds, we have integrated
high-throughput processes, medicinal chemistry, bioinformatics, structural
biology and early in vivo testing into a process that allows us to efficiently
and rapidly identify highly qualified drug candidates that meet our extensive
development criteria.
To date, we have filed 14 investigational new drug applications, or INDs. We
believe that our deep pool of drug candidates will enable us to continue to file
multiple new INDs each year for the foreseeable future. ...
Read SEC Filing on NASDAQ.com »